Meeting
2016 ASCO Annual Meeting
Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET).
Authors
Jonathan R. Strosberg
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Jonathan R. Strosberg , Jennifer A. Chan , Alain C. Mita , Madan Kundu , Sue-zette Valera , Peter Unge , Christelle Darstein , Mike Hu , Edward M. Wolin , James C. Yao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
NCT01364415
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4095)
DOI
10.1200/JCO.2016.34.15_suppl.4095
Abstract #
4095
Poster Bd #
87
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Vorolanib (CM082) in Chinese patients with advanced solid tumor: A phase 1, open-label, dose escalation study.
First Author: Yan Song
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers.
First Author: Scott Kopetz
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas.
First Author: Michael J. Overman
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Tislelizumab combined with anlotinib and chemotherapy (XELOX) in the treatment of advanced gastric carcinoma: Preliminary results of a single-arm, open-label phase I/IIa trial (TALENT study).
First Author: Xiaofeng Chen